Free Trial

Vivani Medical (NASDAQ:VANI) Director Buys $2,399,405.48 in Stock

Vivani Medical logo with Medical background

Key Points

  • Vivani Medical Director Gregg Williams purchased $2.4 million worth of shares, increasing his stake in the company by 14.94%.
  • The company’s stock has risen 21.1% to $1.47 following positive market sentiment and developments related to its weight-loss implant technology.
  • HC Wainwright has reaffirmed a "buy" rating for Vivani Medical, setting a price target of $4.00 per share, indicating optimistic future performance based on market analysis.
  • Five stocks we like better than Vivani Medical.

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 2,068,453 shares of the company's stock in a transaction that occurred on Monday, September 15th. The shares were purchased at an average cost of $1.16 per share, with a total value of $2,399,405.48. Following the completion of the purchase, the director owned 15,909,348 shares in the company, valued at $18,454,843.68. This trade represents a 14.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Vivani Medical Trading Down 4.1%

NASDAQ:VANI traded down $0.06 during trading hours on Friday, reaching $1.41. 171,946 shares of the company were exchanged, compared to its average volume of 139,856. The stock's 50-day moving average is $1.35 and its 200-day moving average is $1.20. The firm has a market cap of $83.53 million, a PE ratio of -3.13 and a beta of 3.12. Vivani Medical, Inc. has a twelve month low of $0.91 and a twelve month high of $1.80.

Vivani Medical (NASDAQ:VANI - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). As a group, research analysts anticipate that Vivani Medical, Inc. will post -0.41 EPS for the current year.

Institutional Trading of Vivani Medical

Several large investors have recently modified their holdings of VANI. Panagora Asset Management Inc. purchased a new position in shares of Vivani Medical during the second quarter valued at approximately $25,000. Wealthedge Investment Advisors LLC purchased a new position in shares of Vivani Medical during the fourth quarter worth approximately $43,000. Jane Street Group LLC bought a new position in shares of Vivani Medical during the fourth quarter valued at approximately $66,000. Northern Trust Corp raised its holdings in shares of Vivani Medical by 19.1% in the fourth quarter. Northern Trust Corp now owns 71,915 shares of the company's stock worth $83,000 after buying an additional 11,540 shares during the last quarter. Finally, Connective Capital Management LLC raised its holdings in shares of Vivani Medical by 796.2% during the first quarter. Connective Capital Management LLC now owns 162,098 shares of the company's stock worth $170,000 after purchasing an additional 144,010 shares during the last quarter. 6.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $4.00 price objective on shares of Vivani Medical in a research report on Tuesday, September 2nd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $4.00.

View Our Latest Analysis on Vivani Medical

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.

Read More

Insider Buying and Selling by Quarter for Vivani Medical (NASDAQ:VANI)

Should You Invest $1,000 in Vivani Medical Right Now?

Before you consider Vivani Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivani Medical wasn't on the list.

While Vivani Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.